Thaler J - Search Results

1

Prognosis and prognostic factors for patients with chronic myeloid leukemia: nontransplant therapy.

Hasford J, Pfirrmann M, Hehlmann R, Baccarani M, Guilhot F, Mahon FX, Kluin-Nelemans HC, Ohnishi K, Thaler J, Steegmann JL; Collaborative CML Prognostic Factors Project Group. Hasford J, et al. Among authors: thaler j. Semin Hematol. 2003 Jan;40(1):4-12. doi: 10.1053/shem.2003.50006. Semin Hematol. 2003. PMID: 12563607 Review.

2

Current controversies on the role of interferon-alpha for therapy of chronic myeloid leukemia.

Heimpel H, Allan NC, Baccarani M, Guilhot F, Hehlmann R, Horowitz M, Kluin-Nelemans J, Schaefer U, Storb R, Thaler J. Heimpel H, et al. Among authors: thaler j. Bone Marrow Transplant. 1996 May;17 Suppl 3:S39. Bone Marrow Transplant. 1996. PMID: 8769699 No abstract available.

3

Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders.

Bonifazi F, de Vivo A, Rosti G, Guilhot F, Guilhot J, Trabacchi E, Hehlmann R, Hochhaus A, Shepherd PC, Steegmann JL, Kluin-Nelemans HC, Thaler J, Simonsson B, Louwagie A, Reiffers J, Mahon FX, Montefusco E, Alimena G, Hasford J, Richards S, Saglio G, Testoni N, Martinelli G, Tura S, Baccarani M; Europena Study Group on Interferon in Chronic Myeloid Leukemia; Italian Cooperative Study Group on CML; France Intergroup of CML; German CML Study Group; UK Medical Research Council Working Party on CML; Spanish CML Study Group; Australian CML Study Group; Swedish CML Study Group. Bonifazi F, et al. Among authors: thaler j. Blood. 2001 Nov 15;98(10):3074-81. doi: 10.1182/blood.v98.10.3074. Blood. 2001. PMID: 11698293 Free article. Review.

4

Idarubicin and intermediate-dose cytarabine for myeloid blast crisis of chronic myelogenous leukemia--results of a phase-II trial.

Schneller F, Schuler M, Schumacher K, Thaler J, Peschel C, Huber C, Aulitzky W. Schneller F, et al. Among authors: thaler j. Ann Hematol. 1998 Nov;77(5):225-9. doi: 10.1007/s002770050447. Ann Hematol. 1998. PMID: 9858148 Clinical Trial.

5

Fluorescence in situ hybridization (FISH) on peripheral blood smears for monitoring Philadelphia chromosome-positive chronic myeloid leukemia (CML) during interferon treatment: a new strategy for remission assessment.

Mühlmann J, Thaler J, Hilbe W, Bechter O, Erdel M, Utermann G, Duba HC. Mühlmann J, et al. Among authors: thaler j. Genes Chromosomes Cancer. 1998 Feb;21(2):90-100. doi: 10.1002/(sici)1098-2264(199802)21:2<90::aid-gcc3>3.0.co;2-2. Genes Chromosomes Cancer. 1998. PMID: 9491319

6

Monitoring of remission status by fluorescence in situ hybridisation in chronic myeloid leukaemia patients treated with interferon-alpha.

Duba HC, Peter S, Hilbe W, Fluckinger T, Fridrik M, Erdel M, Thaler J, Utermann G. Duba HC, et al. Among authors: thaler j. Int J Oncol. 1999 Jan;14(1):145-50. doi: 10.3892/ijo.14.1.145. Int J Oncol. 1999. PMID: 9863021

7

Interferon alpha-2c therapy of patients with chronic myelogenous leukemia: long-term results of a multicenter phase-II study. Austrian Biological Response Modifier (BRM) Study Group.

Thaler J, Gastl G, Fluckinger T, Niederwieser D, Huber H, Seewann H, Sill H, Lang A, Falk M, Duba C, Utermann G, Kühr T, Aulitzky W, Huber C. Thaler J, et al. Ann Hematol. 1996 Jun;72(6):349-55. doi: 10.1007/s002770050185. Ann Hematol. 1996. PMID: 8767103 Clinical Trial.

8

[Value of interferon-alpha in treatment of chronic myeloid leukemia].

Thaler J. Thaler J. Acta Med Austriaca. 1993;20(3):65-9. Acta Med Austriaca. 1993. PMID: 8368048 Review. German.

9

Prophylactic use of interferon alfa after bone marrow transplantation for patients with chronic myelogenous leukemia at high risk of relapse: a pilot study. The Chronic Leukemia Working Party of the EBMT.

Niederwieser D, Arcese W, Bandini G, Schwaighofer H, Thaler J, Bosi A, Di Bartolomeo P, Alessandrino EP, Urban C, Gratwohl A. Niederwieser D, et al. Among authors: thaler j. Semin Hematol. 1993 Jul;30(3 Suppl 3):40-3. Semin Hematol. 1993. PMID: 8235706 Clinical Trial. No abstract available.

10

Treatment of chronic myelogenous leukemia with interferon alfa-2c: response rate and toxicity in a phase II multicenter study. The Austrian Biological Response Modifier (BRM) Study Group.

Thaler J, Gastl G, Fluckinger T, Niederwieser D, Huber H, Seewann H, Silly H, Lang A, Abbrederis C, Gadner H, et al. Thaler J, et al. Semin Hematol. 1993 Jul;30(3 Suppl 3):17-9. Semin Hematol. 1993. PMID: 8235697 Clinical Trial. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

499 results

Search Page